Clinical Trial Update: Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 open-label study evaluating PLX-PAD for COVID-19 and acute respiratory distress syndrome has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• PLX PAD

Snippet

Sponsor: Pluristem Ltd. | Conditions: COVID, ARDS | Phase 2 | Status: TERMINATED